Related Experiment Video
Updated: Dec 27, 2025
07:41
Video Imaging and Spatiotemporal Maps to Analyze Gastrointestinal Motility in Mice
Published on: February 3, 2016
14.6K
Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders
Radomir Juza1,2, Premysl Vlcek1,3, Eva Mezeiova4
1National Institute of Mental Health, Klecany, Czech Republic.
Medicinal Research Reviews
|March 3, 2020
Summary
Serotonin 3 (5-HT3) receptor antagonists, initially used for gastrointestinal issues, show promise for treating CNS disorders like anxiety and depression. Recent research explores novel modulators for these conditions.
Area of Science:
- Neuropharmacology
- Gastroenterology
- Molecular Biology
Background:
- Serotonin (5-hydroxytryptophan [5-HT]) is a key neurotransmitter and signaling molecule.
- 5-HT receptors (5-HTRs) mediate diverse physiological functions.
- The 5-HT3 receptor (5-HT3R) is a ligand-gated ion channel with clinical applications.
Purpose of the Study:
- To review the therapeutic potential of 5-HT3R antagonists.
- To explore applications beyond gastrointestinal disorders, focusing on neuropsychiatric conditions.
- To highlight novel 5-HT3R modulators developed in the last decade.
Main Methods:
- Literature review of published studies on 5-HT3R antagonists.
- Analysis of structure, function, and pharmacology of 5-HT3R modulators.
- Examination of clinical applications in gastrointestinal and neuropsychiatric disorders.
Main Results:
- 5-HT3R antagonists (setrons) are clinically used for chemotherapy-induced nausea/vomiting and IBS.
- Emerging evidence supports their efficacy in treating CNS disorders, including schizophrenia, depression, anxiety, and drug abuse.
- Novel modulators demonstrate improved potency and potentially milder side effect profiles.
Conclusions:
- 5-HT3R antagonists possess significant therapeutic potential for both GI and neuropsychiatric disorders.
- Continued research into novel 5-HT3R modulators may yield new treatments for complex neurological and psychiatric conditions.
Related Concept Videos
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
812
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
812
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
534
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
534
01:23Antidepressant Drugs: MAOIs and Other Agents
705
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
705
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.1K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.1K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
544
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
544
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
373
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
373